Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Non Operating Income (2024 - 2025)

Sangamo Therapeutics has reported Non Operating Income over the past 4 years, most recently at -$21000.0 for Q4 2025.

  • Quarterly results put Non Operating Income at -$21000.0 for Q4 2025, down 101.12% from a year ago — trailing twelve months through Dec 2025 was -$3.6 million (down 181.95% YoY), and the annual figure for FY2025 was -$3.6 million, down 181.95%.
  • Non Operating Income for Q4 2025 was -$21000.0 at Sangamo Therapeutics, down from $107000.0 in the prior quarter.
  • Over the last five years, Non Operating Income for SGMO hit a ceiling of $2.1 million in Q1 2024 and a floor of -$2.5 million in Q2 2025.